Abstract: This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.
Type:
Grant
Filed:
February 8, 2021
Date of Patent:
December 26, 2023
Assignee:
Romark Laboratories L.C.
Inventors:
Jean-Francois Rossignol, J. Edward Semple
Abstract: Disclosed is use of thiazolides, such as nitazoxanide and/or tizoxanide, against viruses belonging to the Coronaviridae family, such as viruses belonging to the Orthocoronavirinae subfamily.
Abstract: The present invention refers to: crystalline tizoxanide amine salts, such as e.g. the ethanolamine salt, the morpholine salt, the propanolamine salt, the piperazine salt and the N-methylpiperazine salt, crystalline amine salts of 2-hydroxy-N-(5-halo-1,3-thiazol-2-yl) benzamide derivatives, such as e.g. the 2-hydroxy-N-(5-chloro-1,3-thiazol-2-yl)benzamide (RM-4848), a method for preparing a tizoxanide amine salt from its prodrug nitazoxanide (NTZ), pharmaceutical compositions comprising tizoxanide amine salts, tizoxanide amine salts for use as an antiviral or antiparasitic agent.
Type:
Application
Filed:
July 19, 2021
Publication date:
September 28, 2023
Applicant:
Romark Laboratories, L.C.
Inventors:
Jean-Francois Rossignol, Andrew V. Stachulski
Abstract: Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analogue thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analogue thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided.
Abstract: Thiazolide compounds, such as nitazoxanide and/or tizoxanide, may be used against viruses belonging to the Picornaviridae family or the Paramyxoviridae family.
Type:
Application
Filed:
October 1, 2021
Publication date:
April 28, 2022
Applicant:
Romark Laboratories L.C.
Inventors:
Jean-Francois Rossignol, Maria Gabriella Santoro
Abstract: Provided are methods of treating a disease or condition associated with an increased level of expression of a protein disulfide-isomerase A3 (PDIA3) by administering to a subject with an increased level of expression of PDIA3 a PDIA3-inhibiting effective amount of a thiazolide compound, such as nitazoxanide or tizoxanide. Also provided are methods of screening for therapeutic agents based on PDIA3 inhibition.
Type:
Grant
Filed:
April 17, 2018
Date of Patent:
November 16, 2021
Assignee:
Romark Laboratories L.C.
Inventors:
Jean-Francois Rossignol, Maria Gabriella Santoro
Abstract: Thiazolide compounds, such as nitazoxanide and/or tizoxanide, may be used against viruses belonging to the Picornaviridae family or the Paramyxoviridae family.
Type:
Grant
Filed:
March 30, 2017
Date of Patent:
October 5, 2021
Assignee:
Romark Laboratories L.C.
Inventors:
Jean-Francois Rossignol, Maria Gabriella Santoro
Abstract: This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.
Type:
Application
Filed:
February 8, 2021
Publication date:
June 17, 2021
Applicant:
Romark Laboratories L.C.
Inventors:
Jean-Francois Rossignol, J. Edward Semple
Abstract: This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.
Type:
Grant
Filed:
June 21, 2019
Date of Patent:
February 9, 2021
Assignee:
Romark Laboratories L.C.
Inventors:
Jean-Francois Rossignol, J. Edward Semple
Abstract: The invention provides for the use of pharmaceutical compositions comprising a thiazolide in the stimulation of the immune system in a subject in need thereof, thereby preventing and/or treating viral diseases, cancer and diseases caused by intracellular protozoan infections.
Abstract: Prodrugs of tizoxanide, an analogue or salt thereof are disclosed. The prodrugs have an ester moiety comprising an amino acid moiety, and increase the bioavailability of the tizoxanide, an analogue or salt thereof. Compositions and methods of treating an intracellular protozoan infection, a viral infection or a cancer are also disclosed.
Type:
Grant
Filed:
May 23, 2019
Date of Patent:
March 3, 2020
Assignee:
Romark Laboratories, L.C.
Inventors:
Jean-Francois Rossignol, Andrew Stachulski
Abstract: Provided are methods of treating a disease or condition associated with an increased level of expression of a protein disulfide-isomerase A3 (PDIA3) by administering to a subject with an increased level of expression of PDIA3 a PDI A3-inhibiting effective amount of a thiazolide compound, such as nitazoxanide or tizoxanide. Also provided are methods of screening for therapeutic agents based on PDIA3 inhibition.
Type:
Application
Filed:
April 17, 2018
Publication date:
February 6, 2020
Applicant:
Romark Laboratories L.C.
Inventors:
Jean-Francois Rossignol, Maria Gabriella Santoro
Abstract: This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.
Type:
Application
Filed:
June 21, 2019
Publication date:
October 10, 2019
Applicant:
Romark Laboratories L.C.
Inventors:
Jean-Francois Rossignol, J. Edward Semple
Abstract: The invention provides for the use of pharmaceutical compositions comprising a thiazolide in the stimulation of the immune system in a subject in need thereof, thereby preventing and/or treating viral diseases, cancer and diseases caused by intracellular protozoan infections
Abstract: Prodrugs of tizoxanide, an analogue or salt thereof are disclosed. The prodrugs have an ester moiety comprising an amino acid moiety, and increase the bioavailability of the tizoxanide, an analogue or salt thereof. Compositions and methods of treating an intracellular protozoan infection, a viral infection or a cancer are also disclosed.
Type:
Application
Filed:
May 23, 2019
Publication date:
September 12, 2019
Applicant:
Romark Laboratories, L.C.
Inventors:
Jean-Francois Rossignol, Andrew Stachulski
Abstract: Solid dosage formulations of nitazoxanide or a nitazoxanide analog are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analog thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analog thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided.
Abstract: This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.
Type:
Grant
Filed:
November 16, 2017
Date of Patent:
July 30, 2019
Assignee:
Romark Laboratories L.C.
Inventors:
Jean-Francois Rossignol, J. Edward Semple
Abstract: Prodrugs of tizoxanide, an analog or salt thereof are disclosed. The prodrugs have an ester moiety comprising an amino acid moiety, and increase the bioavailability of the tizoxanide, an analog or salt thereof. Compositions and methods of treating an intracellular protozoan infection, a viral infection or a cancer are also disclosed.
Type:
Grant
Filed:
October 5, 2018
Date of Patent:
July 23, 2019
Assignee:
Romark Laboratories, L.C.
Inventors:
Jean-Francois Rossignol, Andrew Stachulski
Abstract: The invention provides for the use of pharmaceutical compositions comprising a thiazolide in the stimulation of the immune system in a subject in need thereof, thereby preventing and/or treating viral diseases, cancer and diseases caused by intracellular protozoan infections.